RU2005131011A - Замещенные производные бензоилуреидопиридилпиперидин-и-пирролидинкарбоновой кислоты, способ их получения и их применение - Google Patents
Замещенные производные бензоилуреидопиридилпиперидин-и-пирролидинкарбоновой кислоты, способ их получения и их применение Download PDFInfo
- Publication number
- RU2005131011A RU2005131011A RU2005131011/04A RU2005131011A RU2005131011A RU 2005131011 A RU2005131011 A RU 2005131011A RU 2005131011/04 A RU2005131011/04 A RU 2005131011/04A RU 2005131011 A RU2005131011 A RU 2005131011A RU 2005131011 A RU2005131011 A RU 2005131011A
- Authority
- RU
- Russia
- Prior art keywords
- alkyl
- agonists
- inhibitors
- compounds
- coo
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract 7
- 239000002253 acid Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 14
- 239000003814 drug Substances 0.000 claims abstract 9
- 150000003839 salts Chemical class 0.000 claims abstract 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 38
- 239000000556 agonist Substances 0.000 claims 15
- 239000003112 inhibitor Substances 0.000 claims 5
- 239000013543 active substance Substances 0.000 claims 4
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 3
- 230000001419 dependent effect Effects 0.000 claims 3
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims 2
- 229940127470 Lipase Inhibitors Drugs 0.000 claims 2
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims 2
- 239000003613 bile acid Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000000122 growth hormone Substances 0.000 claims 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 2
- SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 229940123208 Biguanide Drugs 0.000 claims 1
- 102000013585 Bombesin Human genes 0.000 claims 1
- 108010051479 Bombesin Proteins 0.000 claims 1
- 102000019432 Galanin Human genes 0.000 claims 1
- 101800002068 Galanin Proteins 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022489 Insulin Resistance Diseases 0.000 claims 1
- 102000000853 LDL receptors Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 108010092277 Leptin Proteins 0.000 claims 1
- 102000016267 Leptin Human genes 0.000 claims 1
- 102000004882 Lipase Human genes 0.000 claims 1
- 239000004367 Lipase Substances 0.000 claims 1
- 108090001060 Lipase Proteins 0.000 claims 1
- 108010013563 Lipoprotein Lipase Proteins 0.000 claims 1
- 102100022119 Lipoprotein lipase Human genes 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 229940124757 MC-4 agonist Drugs 0.000 claims 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims 1
- 102000002512 Orexin Human genes 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229940124754 PPAR-alpha/gamma agonist Drugs 0.000 claims 1
- 102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 claims 1
- 108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 claims 1
- 102100038831 Peroxisome proliferator-activated receptor alpha Human genes 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 229940123464 Thiazolidinedione Drugs 0.000 claims 1
- 102100031241 Thioredoxin reductase 2, mitochondrial Human genes 0.000 claims 1
- 108010071769 Thyroid Hormone Receptors beta Proteins 0.000 claims 1
- 102000005630 Urocortins Human genes 0.000 claims 1
- 108010059705 Urocortins Proteins 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 239000003392 amylase inhibitor Substances 0.000 claims 1
- 229940125708 antidiabetic agent Drugs 0.000 claims 1
- 239000003472 antidiabetic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 1
- 229940125388 beta agonist Drugs 0.000 claims 1
- 150000004283 biguanides Chemical class 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 230000023852 carbohydrate metabolic process Effects 0.000 claims 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000003354 cholesterol ester transfer protein inhibitor Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940125753 fibrate Drugs 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 230000002218 hypoglycaemic effect Effects 0.000 claims 1
- 239000000411 inducer Substances 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 229940039781 leptin Drugs 0.000 claims 1
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 claims 1
- 235000019421 lipase Nutrition 0.000 claims 1
- -1 lipase inhibitors Substances 0.000 claims 1
- 230000037356 lipid metabolism Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002697 lyase inhibitor Substances 0.000 claims 1
- 229950004994 meglitinide Drugs 0.000 claims 1
- SLZIZIJTGAYEKK-CIJSCKBQSA-N molport-023-220-247 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CNC=N1 SLZIZIJTGAYEKK-CIJSCKBQSA-N 0.000 claims 1
- 230000002474 noradrenergic effect Effects 0.000 claims 1
- 108060005714 orexin Proteins 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 229960003975 potassium Drugs 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 229940076279 serotonin Drugs 0.000 claims 1
- 239000000952 serotonin receptor agonist Substances 0.000 claims 1
- 230000002295 serotoninergic effect Effects 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- 239000004059 squalene synthase inhibitor Substances 0.000 claims 1
- 150000001467 thiazolidinediones Chemical class 0.000 claims 1
- 239000000777 urocortin Substances 0.000 claims 1
- NMDAFFPZWCMMLW-UHFFFAOYSA-N n-[(1-pyridin-2-ylpiperidin-2-yl)carbamoyl]benzamide Chemical class C=1C=CC=CC=1C(=O)NC(=O)NC1CCCCN1C1=CC=CC=N1 NMDAFFPZWCMMLW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10309929A DE10309929B4 (de) | 2003-03-07 | 2003-03-07 | Substituierte Benzoylureidopyridyl-piperidin- und -pyrrolidin-carbonsäurederivate, Verfahren zu deren Herstellung und deren Verwendung |
| DE10309929.8 | 2003-03-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005131011A true RU2005131011A (ru) | 2006-05-10 |
Family
ID=32945839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005131011/04A RU2005131011A (ru) | 2003-03-07 | 2004-02-21 | Замещенные производные бензоилуреидопиридилпиперидин-и-пирролидинкарбоновой кислоты, способ их получения и их применение |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1603895B1 (OSRAM) |
| JP (1) | JP2006519795A (OSRAM) |
| KR (1) | KR20050108487A (OSRAM) |
| CN (1) | CN1759109A (OSRAM) |
| AT (1) | ATE386735T1 (OSRAM) |
| AU (1) | AU2004218267A1 (OSRAM) |
| BR (1) | BRPI0408148A (OSRAM) |
| CA (1) | CA2518322A1 (OSRAM) |
| CO (1) | CO5690587A2 (OSRAM) |
| DE (2) | DE10309929B4 (OSRAM) |
| HR (1) | HRP20050779A2 (OSRAM) |
| MA (1) | MA27745A1 (OSRAM) |
| MX (1) | MXPA05009122A (OSRAM) |
| NO (1) | NO20054418L (OSRAM) |
| PL (1) | PL377293A1 (OSRAM) |
| RU (1) | RU2005131011A (OSRAM) |
| WO (1) | WO2004078743A1 (OSRAM) |
| ZA (1) | ZA200506119B (OSRAM) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006055435A1 (en) | 2004-11-15 | 2006-05-26 | Bristol-Myers Squibb Company | 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors |
| WO2006053274A2 (en) | 2004-11-15 | 2006-05-18 | Bristol-Myers Squibb Company | 2-amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7226942B2 (en) | 2004-11-15 | 2007-06-05 | Bristol-Myers Squibb Company | 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| US7365061B2 (en) | 2004-11-15 | 2008-04-29 | Bristol-Myers Squibb Company | 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| MX2012003389A (es) * | 2009-10-06 | 2012-04-10 | Bristol Myers Squibb Co | Moduladores de gpr40 de pirrolidina. |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3034004A1 (de) * | 1980-09-10 | 1982-04-22 | Hoechst Ag, 6000 Frankfurt | Sulfonylharnstoffe, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen und ihre verwendung |
| DE10116768A1 (de) * | 2001-04-04 | 2002-10-10 | Aventis Pharma Gmbh | Acylphenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2411082A1 (en) * | 2000-06-09 | 2002-12-05 | Aventis Pharma Deutschland Gmbh | Acylphenyl urea derivatives, methods for the production thereof and use thereof as a medicament |
| DE10125567B4 (de) * | 2001-05-25 | 2004-08-26 | Aventis Pharma Deutschland Gmbh | Carbonamid substituierte Phenylharnstoffderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| PE20021091A1 (es) * | 2001-05-25 | 2003-02-04 | Aventis Pharma Gmbh | Derivados de fenilurea sustituidos con carbonamida y procedimiento para su preparacion |
| IL164249A0 (en) * | 2002-04-11 | 2005-12-18 | Aventis Pharma Gmbh | Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use |
| CA2493373A1 (en) * | 2002-07-11 | 2004-01-22 | Aventis Pharma Deutschland Gmbh | Urea-substituted and urethane-substituted acylureas, methods for the production thereof and their use as medicaments |
| AU2003249937A1 (en) * | 2002-07-12 | 2004-02-02 | Sanofi-Aventis Deutschland Gmbh | Heterocyclically substituted benzoylureas, method for their production and their use as medicaments |
-
2003
- 2003-03-07 DE DE10309929A patent/DE10309929B4/de not_active Expired - Fee Related
-
2004
- 2004-02-21 KR KR1020057016583A patent/KR20050108487A/ko not_active Withdrawn
- 2004-02-21 CA CA002518322A patent/CA2518322A1/en not_active Abandoned
- 2004-02-21 EP EP04713467A patent/EP1603895B1/de not_active Expired - Lifetime
- 2004-02-21 BR BRPI0408148-0A patent/BRPI0408148A/pt not_active IP Right Cessation
- 2004-02-21 AT AT04713467T patent/ATE386735T1/de not_active IP Right Cessation
- 2004-02-21 WO PCT/EP2004/001735 patent/WO2004078743A1/de not_active Ceased
- 2004-02-21 HR HR20050779A patent/HRP20050779A2/xx not_active Application Discontinuation
- 2004-02-21 RU RU2005131011/04A patent/RU2005131011A/ru not_active Application Discontinuation
- 2004-02-21 DE DE502004006253T patent/DE502004006253D1/de not_active Expired - Lifetime
- 2004-02-21 AU AU2004218267A patent/AU2004218267A1/en not_active Abandoned
- 2004-02-21 CN CNA2004800062407A patent/CN1759109A/zh active Pending
- 2004-02-21 JP JP2006504448A patent/JP2006519795A/ja not_active Ceased
- 2004-02-21 MX MXPA05009122A patent/MXPA05009122A/es unknown
- 2004-02-21 PL PL377293A patent/PL377293A1/pl not_active Application Discontinuation
-
2005
- 2005-08-01 ZA ZA200506119A patent/ZA200506119B/en unknown
- 2005-09-06 CO CO05089471A patent/CO5690587A2/es not_active Application Discontinuation
- 2005-09-07 MA MA28485A patent/MA27745A1/fr unknown
- 2005-09-23 NO NO20054418A patent/NO20054418L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA27745A1 (fr) | 2006-02-01 |
| EP1603895A1 (de) | 2005-12-14 |
| DE10309929B4 (de) | 2006-02-23 |
| BRPI0408148A (pt) | 2006-03-01 |
| PL377293A1 (pl) | 2006-01-23 |
| CA2518322A1 (en) | 2004-09-16 |
| CO5690587A2 (es) | 2006-10-31 |
| JP2006519795A (ja) | 2006-08-31 |
| KR20050108487A (ko) | 2005-11-16 |
| CN1759109A (zh) | 2006-04-12 |
| WO2004078743A1 (de) | 2004-09-16 |
| HRP20050779A2 (en) | 2006-10-31 |
| ZA200506119B (en) | 2006-11-29 |
| EP1603895B1 (de) | 2008-02-20 |
| MXPA05009122A (es) | 2005-10-20 |
| AU2004218267A1 (en) | 2004-09-16 |
| NO20054418L (no) | 2005-09-23 |
| ATE386735T1 (de) | 2008-03-15 |
| DE502004006253D1 (de) | 2008-04-03 |
| DE10309929A1 (de) | 2004-12-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008105756A (ru) | Производные 1,4-бензотиазепин-1,1-диоксида, способ их получения, лекарственное средство, содержащее эти соединения и их применение в качестве гиполипидемических средств | |
| JP2006502247A5 (OSRAM) | ||
| RU2006131306A (ru) | Производные 7-фениламино-4-хинолон-3-карбоновой кислоты, способ их получения и их применение в качестве лекарственных средств | |
| JP2009536629A5 (OSRAM) | ||
| RU2005128497A (ru) | Замещенные производные гексагидропиразино (1,2-а) пиримидин-4,7-диона, способы их получения и их применение в качестве лекарственных средств | |
| RU2005133631A (ru) | Новый дифенилазетидинон с улучшенными физиологическими свойствами, способы его получения, содержащие эти соединения лекарственные средства и их применение | |
| JP2009536626A5 (OSRAM) | ||
| RU2009122470A (ru) | Новые бензилзамещенные производные 1,4-бензотиепин-1,1-диоксида, способ их получения, лекарственные средства, содержащие такие соединения, и их применение | |
| Chan et al. | Regulation and role of transcription factors in osteogenesis | |
| RU2010115748A (ru) | (карбоксилалкиленфенил) фенилоксаламиды, способ их получения и их применение в качестве лекарственного средства | |
| RU2008148838A (ru) | Фениламинобензоксазолзамещенные карбоновые кислоты, способ их получения и их применение в качестве лекарственных средств | |
| JP2009536627A5 (OSRAM) | ||
| AU726659B2 (en) | Calcilytic compounds | |
| RU2010115747A (ru) | (циклопропилфенил)фенилоксаламиды, способ их получения и их применения в качестве лекарственного средства | |
| RU2005101088A (ru) | Катионозамещенные дифенилазетидиноны, способ их получения, лекарственные средства, содержащие эти соединения, и их применение | |
| Pechanova et al. | Peripheral and central effects of melatonin on blood pressure regulation | |
| RU2005128499A (ru) | Замещенные у азота производные гексагидропиразино (1,2-а) пиримидин-4, 7-диона, способ их получения и их применение в качестве лекарственного средства | |
| RU2007142657A (ru) | Производные азола в качестве ингибиторов липаз и фосфолипаз | |
| HRP20110009T1 (hr) | Spoj kojim se aktivira ppar i farmaceutski pripravak koji ga sadrži | |
| RU2006147245A (ru) | Замещенные производные оксазол-бензоизотиазолдиоксида, способ их получения и их применения | |
| RU2004108120A (ru) | Комбинированные препараты из арилзамещенных производных пропаноламина с другими биологически активными веществами и их применение | |
| BRPI0412219B8 (pt) | compostos ômega-carboxi aril difenil uréia fluoro substituídos e composições farmacêuticas compreendendo os referidos compostos | |
| DE602004017174D1 (de) | Phenoxyessigsäure-derivate zur behandlung von störungen der atemwege | |
| Silenieks et al. | Evaluation of selective 5-HT2C agonists in acute seizure models | |
| ATE525350T1 (de) | Substituierte n-phenyl- bipyrrolidincarbonsäureamide und deren therapeutische verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20071119 |